Resveratrol (Jotrol) in Parkinson’s: a 3-month comparison of two doses vs placebo

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2a, randomized, double-arm dose-escalation study in Parkinson’s disease. Thirty participants will be assigned to 200 mg Jotrol, 400 mg Jotrol, or matching placebo once daily for 3 months, with safety, tolerability, PK/PD, and biomarkers explored. An optional sub-study may collect cerebrospinal fluid biomarkers to further understand drug effects. Enrollment spans about one year across roughly three US centers, with total study participation of 4–5 months per participant.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Capable of providing informed consent (IC) and complying with study procedures
* Stable on Levodopa and/or DA agonists for at least 4 weeks before enrollment
* Clinical diagnosis of PD according to UK Brain Bank criteria and/or PD with Dementia (PDD) by MDS criteria (53-55).
* MoCA≥18.
* Hohn and Yahr stage 2 and 3
* Age of 55-85 years, medically stable
* English Fluency

Exclusion Criteria:

* Known PD-linked gene mutations e.g. PINK-1, DJ-1, parkin, LRRK2 etc.
* Clinical signs indicating syndromes or disorders other than PD including, Alzheimer's Disease (AD), corticobasal degeneration (CBD), supranuclear gaze palsy, multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), frontal dementia, history of stroke, head injury or encephalitis, cerebellar signs, early severe autonomic involvement
* Any psychiatric diagnosis or symptoms, (e.g., hallucinations and suicidality, major depression, or delusions) that could interfere with study procedures
* Medical history of liver or pancreatic disease, GI, ulcers and Chron's disease, kidney, or blood problems. Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG at Screening or Baseline. Any other medical conditions (e.g., cardiac, respiratory, GI, renal disease) which are not adequately controlled, or which in the opinion of the investigator(s) could affect the subject's safety or interfere with the study assessments and are below grade 3 criteria as outlined in table 2.
* Enrolled as an active participant in another clinical study
* Anti-coagulant medications, including Coumadin, heparin, enoxaparin, fondaparinux etc.
* Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressant's, or plasmapheresis during the
* Geriatric Depression Scale (GDS) score greater than or equal to 8 at Screening.
* Answer "yes" to C-SSRS suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before Screening, at Screening, or at the Baseline Visit, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening.
* Planned surgery which requires general anesthesia that would take place during the study.
* Severe visual or hearing impairment that would prevent the subject from performing psychometric tests accurately.
* Women of Childbearing Potential (WCBP) or lactating.
* Must not be on any nutritional or medicinal supplements at least 6 weeks prior to enrollment.

Where it's running

• Georgetown University Hospital
  Washington D.C., District of Columbia, United States Recruiting

Study contacts

• Principal investigator: Fernando Pagan, M.D. — Georgetown University
• Study coordinator: Luke Lovelace, BS, MBA
• Email: ll928@georgetown.edu
• Phone: 757-802-5001

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ginger as a Modifier of Ghrelin Levels in Parkinson’s Disease and REM Sleep Behavior Disorder

  This study tests whether ginger capsules can raise ghrelin levels in people with Parkinson’s disease, REM sleep behavior disorder, and healthy controls.

  Recruiting Cambridge University Hospitals NHS Foundation Trust · Cambridge · NCT07882108

• Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment

  This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07868614

• Mental imagery with self-regulation to help daily activities in Parkinson's disease

  This study tests whether a six-week program of mental imagery combined with self-regulation can help people with Parkinson’s perform daily activities better than standard learning or exercise.

  Recruiting The Hong Kong Polytechnic University · Hong Kong · NCT07860294

• Real-world experiences of Inbrija for Parkinson's OFF episodes

  This study looks at how people with Parkinson’s who use Inbrija for OFF episodes feel and function in daily life.

  Recruiting Merz Pharmaceuticals GmbH · Altmünster and 1 other locations · NCT07797790

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Test of RO7568282 in early Parkinson's disease

  This study tests whether RO7568282, compared with placebo, is safe and helps people with early Parkinson's disease who are already taking levodopa.

  Recruiting at 4 sites Phase 2 Hoffmann-La Roche · Boca Raton, Florida and 3 other locations · NCT07781644

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.